Background Iguratimod is a newly-developed small molecular anti-rheumatic drug, which can inhibit the effects of prostaglandin E2, TNF-α and IL-17. had been reported to be effective in treatment SpA. was implied potential efficacy on ax-SpA. Objectives This study aimed demonstrated safety activity ax-SpA (ASDAS>2.1). Methods We performed meta-analysis systemically evaluate by gathering publi...